Alloy is Building the World's First Fully Integrated Product Development
Organization - Read the full article
Advancing Differentiated Bispecific Antibodies in Autoimmune Disease
How Cantai and Alloy designed and advanced high-performance bispecifics by engineering against known failure modes from day one
Designing Bispecifics That Hold Up in the Real World
How Alloy’s integrated model helped Cantai move faster and design with greater precision
Discovery of highly-specific TCR mimic antibodies to WT1
Navigating high homology: Discovery of TCR mimic antibodies with greater specificity to Wilms tumor 1 antigen The development of TCR mimic (TCRm) antibodies (or TCR-like antibodies) offers a promising new approach for cancer immunotherapy but identifying TCRm antibody candidates with optimal specificity and low off-target effects can be challenging. Here, we look at an antibody […]
ATX-Gx™ Biotech Licensee Discovering Novel Therapeutics
Dren Bio leveraged Alloy Therapeutics’ ATX-Gx™ humanized mouse platform and Discovery Services to successfully identify a high-quality lead candidate for its Enhanced ADCC Program. This partnership underscores the effectiveness of Alloy’s royalty-free licensing model and integrated discovery support in helping biotech startups rapidly advance oncology and autoimmune programs toward the clinic. Alloy has more than […]
Partnering with Target-Rich Biotech Companies
Alloy Therapeutics collaborates with “target-rich” biotech companies through its 82VS venture studio to launch asset-centric joint ventures that accelerate drug discovery. By providing end-to-end Discovery Services and company creation support, Alloy enables partners to produce high-value targets and move promising treatments toward the clinic without traditional capital constraints. Running a successful early-stage biotech company requires […]
Democratizing Access for Academic Entrepreneurs
We are advancing Alloy as a biotechnology ecosystem company, because we believe strongly that the innovation and breakthroughs that result from a network of relationships are far more powerful than those that can advance from silos. We collaborate with everyone to compete against disease. An exciting element of this dynamic is how under-resourced, smaller teams […]